Video

Overview of Antibody Drug Conjugates in Lung Cancer

Author(s):

Martin Dietrich, MD, PhDWade Thomas Iams, MD

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Related Videos
Marina Chiara Garassino, MD
Nicolas Girard, MD
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Nicolas Girard, MD
Shirish M. Gadgeel, MD
Jacob Sands, MD
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Charu Aggarwal, MD, MPH, FASCO
Andrea Wolf, MD, MPH
Related Content
John V. Heymach, MD, PhD
October 9th 2024

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Kristin A. Higgins, MD, chief clinical officer, City of Hope Cancer Center Atlanta
October 6th 2024

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Isabel Preeshagul, DO, MBS
October 4th 2024

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC